XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatch, Stephanie B, Swift, Lonnie P, Caporali, Simona, Carter, Rebecca, Hill, Esme J, MacGregor, Thomas P, D’Atri, Stefania, Middleton, Mark R, McHugh, Peter J, Sharma, Ricky A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955/
https://www.ncbi.nlm.nih.gov/pubmed/23982883
http://dx.doi.org/10.1002/ijc.28454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955/
https://www.ncbi.nlm.nih.gov/pubmed/23982883
http://dx.doi.org/10.1002/ijc.28454

Ejemplares similares